Dr. Wang Zhongmin (王忠敏) - Director of Interventional Radiology at Ruijin Hospital, Shanghai Jiao Tong University

About Dr. Wang Zhongmin

Dr. Wang Zhongmin (王忠敏) is one of China's most distinguished interventional radiologists and a nationally recognized authority on minimally invasive image-guided tumor therapy. He serves as Director of the Department of Interventional Radiology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and holds the title of Chief Physician and Professor.

Over a career spanning more than three decades, Dr. Wang has established Ruijin Hospital's Interventional Radiology Department as one of the premier minimally invasive oncology centers in China. He is particularly renowned for his expertise in transarterial chemoembolization (TACE), thermal ablation therapies (radiofrequency ablation, microwave ablation, cryoablation), and portal hypertension intervention — areas where his contributions have shaped national clinical guidelines and influenced interventional oncology practice across Asia.

International patients with liver cancer, lung cancer, kidney cancer, or other solid tumors seeking minimally invasive treatment options in China consistently identify Dr. Wang as one of the top interventional oncologists to consult.

Professional Positions and Affiliations

• Director, Department of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
• Past Chairman, Chinese Society of Interventional Radiology
• Editorial Board Member: CardioVascular and Interventional Radiology (CVIR), Journal of Vascular and Interventional Radiology (JVIR), European Radiology
• Fellow, Society of Interventional Radiology (SIR)
• Fellow, Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
• Principal Investigator, multiple national and international multicenter clinical trials in interventional oncology

Specialties and Clinical Expertise

Dr. Wang's clinical practice encompasses the full spectrum of interventional radiology, with particular depth in oncologic intervention and vascular procedures. His approach integrates the latest imaging technology with precision minimally invasive techniques to deliver effective tumor treatment with minimal impact on quality of life.

• Transarterial Chemoembolization (TACE) — conventional TACE and drug-eluting bead TACE (DEB-TACE) for hepatocellular carcinoma (HCC), liver metastases, and cholangiocarcinoma; combination with systemic therapy (sorafenib, lenvatinib, atezolizumab/bevacizumab)
• Thermal Ablation — radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation for liver, lung, kidney, adrenal, and bone tumors; curative-intent ablation for early-stage HCC and renal cell carcinoma
• Irreversible Electroporation (IRE/NanoKnife) — non-thermal ablation for tumors adjacent to critical structures (bile ducts, blood vessels, bowel)
• Transarterial Radioembolization (TARE/SIRT) — Yttrium-90 microsphere therapy for unresectable HCC and liver metastases
• Portal Hypertension Intervention — transjugular intrahepatic portosystemic shunt (TIPS) for variceal bleeding and refractory ascites; partial splenic embolization
• Biliary Intervention — percutaneous transhepatic biliary drainage (PTBD), biliary stenting for malignant and benign strictures, and cholangioscopy-guided therapy
• Vascular Intervention — endovascular treatment of aortic aneurysm (EVAR/TEVAR), peripheral arterial disease, deep vein thrombosis, and pulmonary embolism
• Tumor Biopsy — CT- and ultrasound-guided percutaneous biopsy for tissue diagnosis of deep-seated tumors; liquid biopsy coordination
• Pain Management — celiac plexus neurolysis for pancreatic cancer pain; vertebroplasty and kyphoplasty for painful vertebral metastases

Academic and Research Contributions

Dr. Wang Zhongmin has published over 220 peer-reviewed papers in leading international radiology and oncology journals, with a particular focus on the optimization of TACE protocols for hepatocellular carcinoma and the development of combination strategies integrating interventional therapy with systemic immunotherapy and targeted agents.

His landmark research on DEB-TACE versus conventional TACE in Chinese HCC patients has been widely cited and has influenced treatment selection guidelines across Asia. He has also contributed pivotal data on the safety and efficacy of microwave ablation for large HCC tumors — a technically challenging scenario where his group's outcomes have set international benchmarks.

Dr. Wang has led or co-led numerous multicenter trials evaluating TACE plus sorafenib, TACE plus PD-1 inhibitors, and ablation plus immunotherapy combinations — bringing combination interventional-systemic approaches to Chinese patients and contributing to the global evidence base for these strategies.

He is a past Chairman of the Chinese Society of Interventional Radiology and a Fellow of both SIR and CIRSE, reflecting his standing in the global interventional radiology community. He is a regular invited speaker at SIR, CIRSE, and ESIR (European School of Interventional Radiology) annual meetings.

Approach to Patient Care

Dr. Wang is known for his meticulous, image-guided precision and his commitment to offering minimally invasive alternatives to patients who may not be candidates for surgery or who wish to avoid the morbidity of open procedures. He leads a multidisciplinary tumor board that brings together interventional radiologists, hepatobiliary surgeons, medical oncologists, and radiation oncologists to develop individualized treatment plans for each patient.

For international patients — many of whom arrive with imaging and pathology from overseas institutions — Dr. Wang takes particular care to review all available cross-sectional imaging (CT, MRI, PET-CT) before forming an independent clinical opinion on the feasibility and optimal approach for interventional treatment. His familiarity with international staging systems and treatment guidelines makes him an ideal consultant for patients seeking minimally invasive oncology options in China.

Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Ruijin Hospital is one of China's most prestigious academic medical centers. The Department of Interventional Radiology at Ruijin is a National Key Clinical Specialty and one of the highest-volume interventional oncology centers in China. The department operates:

• Multiple state-of-the-art Angiography Suites with flat-panel detector technology and cone-beam CT capability
• A dedicated Ablation Theater with CT and ultrasound guidance for thermal and non-thermal ablation procedures
• A TIPS and Portal Hypertension Program — one of the highest-volume in China
• A Y-90 Radioembolization Program for liver cancer
• A Multidisciplinary Liver Cancer MDT meeting weekly, integrating interventional radiology, hepatobiliary surgery, and medical oncology

Why International Patients Choose Dr. Wang Zhongmin

• China's leading interventional oncologist — past Chairman of the Chinese Society of Interventional Radiology
• Full spectrum of ablation and embolization techniques — RFA, MWA, cryoablation, IRE, TACE, DEB-TACE, and Y-90
• Combination therapy expertise — integrating interventional procedures with immunotherapy and targeted agents
• Minimally invasive alternative to surgery — ideal for patients who are not surgical candidates or prefer less invasive approaches
• SIR and CIRSE Fellow — internationally credentialed and aligned with global interventional radiology standards
• Second opinion authority — regularly reviews overseas imaging and treatment plans for international patients
• English-language support available through CMCS concierge coordination

Practical Information for International Patients

• Hospital: Ruijin Hospital, 197 Ruijin Er Road, Huangpu District, Shanghai
• Appointment Lead Time: 1″3 weeks for new patients; urgent cases may be expedited through CMCS
• Pre-consultation: Overseas imaging (CT, MRI, PET-CT) can be reviewed remotely before travel through CMCS
• Languages: Mandarin Chinese; English interpretation provided by CMCS
• Medical Records: CMCS provides full translation of overseas imaging reports, pathology, and treatment history into Chinese prior to consultation

How CMCS Can Help

China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking consultation or treatment with Dr. Wang Zhongmin at Ruijin Hospital. Our services include:

• Priority appointment booking and scheduling coordination
• Overseas imaging and pathology report translation (English ↔ Chinese)
• Remote pre-consultation imaging review facilitation
• On-site interpretation during consultations and procedures
• Accommodation coordination near Ruijin Hospital
• Insurance liaison and billing support
• Post-procedure follow-up coordination with your home country oncologist
• Clinical trial eligibility assessment for interventional oncology studies

📧 Contact us: contract@medicalsh.com 
🌐 medicalsh.com